Generic Forfivo XL Availability
FORFIVO XL (bupropion hydrochloride - tablet, extended release;oral)
Manufacturer: EDGEMONT PHARMS LLC
Approval date: November 10, 2011
Strength(s): 450MG [RLD]
Has a generic version of Forfivo XL been approved?
No. There is currently no therapeutically equivalent version of Forfivo XL available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Forfivo XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Sustained-release bupropion and bupropion/mecamylamine tablets
Issued: March 9, 2010
Inventor(s): Zerbe; Horst G. & Paiement; Nadine
Assignee(s): Intelgenx Corp.
Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which then is coated, with a means to provide delayed release, such as with an enteric coating composition. The mecamylamine hydrochloride can be contained in a second granule comprising a hydroxyalkylcellulose.Patent expiration dates:
- June 25, 2027✓
- June 25, 2027
- Forfivo XL Consumer Information (Drugs.com)
- Forfivo XL extended-release tablets Consumer Information (Wolters Kluwer)
- Forfivo XL Consumer Information (Cerner Multum)
- Forfivo XL Advanced Consumer Information (Micromedex®)
- Bupropion Consumer Information (Drugs.com)
- Bupropion Consumer Information (Wolters Kluwer)
- Bupropion extended-release tablets Consumer Information (Wolters Kluwer)
- Bupropion hydrobromide extended-release tablets Consumer Information (Wolters Kluwer)
- Bupropion sustained-release tablets Consumer Information (Wolters Kluwer)
- Bupropion Consumer Information (Cerner Multum)
- Bupropion Advanced Consumer Information (Micromedex®)
- Bupropion Hydrochloride AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|